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Objectives: We report the results of the first head-to-head trial designed to compare the efficacy of 
alendronate and risedronate for the treatment of osteoporosis. 
Methods: The 3-month, randomized, double-blind, multicenter international study enrolled 550 
postmenopausal women, 60-90 year old (mean, 69), with osteoporosis defined by low BMD T-score (either 
lumbar spine or total hip/femoral neck <= -2.5, or <= -2.0 at both sites). The primary endpoint was 3-month 
change in urinary N-telopeptides of type 1 collagen/creatinine (NTx), a marker of bone resorption. Patients 
maintained a calcium intake of at least 1000 mg daily through food and/or calcium supplements. Patients 
were randomized into three treatment groups: alendronate 70mg once weekly using standard am. dosing; 
risedronate 5mg daily dosed 2 hours after a meal and at least 2 hr before the next; or matching placebo for 
each. 
Results: Results are based on an intention-to-treat analysis of urinary NTx for the initial 351 patients 
completing Month 3. 
Tests for between treatment comparison of alendronate vs risedronate, alendronate vs placebo, and 
risedronate vs placebo had p-values <0.001. 
 
Table: Percent Change in Bone Resorption from Baseline at Month 3 ***: 
p<=0.001: Within-treatment test of mean=0
Placebo (N=69) Alendronate (N=129) Risedronate (N=139)
Mean Mean ± SE Mean Mean ± SE Mean Mean ± SE




Conclusion: In this study, alendronate produced a 50% greater reduction in bone resorption than did 
risedronate. This difference may be due to the superior anti-resorptive efficacy of alendronate 70 mg once 
weekly, reduced bioavailability of risedronate resulting from post-meal dosing, or both. 
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